Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

NHS England to Vertex: come clean on Orkambi offer

NHS England to Vertex: come clean on Orkambi offer

NHS England wants Vertex Pharma to waive its non-disclosure agreement on the price it intends to charge for cystic fibrosis drug Orkambi so the public can “form their own ... Vertex’s list price for Orkambi is around £100, 000 a year per patient,

Latest news

  • Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’ Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’

    Vertex to Theresa May: Orkambi verdict ‘ threatens bio investment’. CEO writes open letter to prime minister. ... Fresh from the news that the NHS in England still isn’t minded to fund treatment with its cystic fibrosis therapy Orkambi, Vertex

  • Reshma Kewalramani joins Vertex Pharmaceuticals as CMO Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

    Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani. ... Jeffrey Leiden, chairman, president and chief executive officer of Vertex,

  • Vertex's two-drug cystic fibrosis treatment cleared in US Vertex's two-drug cystic fibrosis treatment cleared in US

    Vertex's two-drug cystic fibrosis treatment cleared in US. FDA approves Symdeko, which combines Kalydeco and tezacaftor. ... Vertex Pharma has won an FDA green light for a third product for cystic fibrosis, and its second combination therapy for the

  • Vertex's tezacaftor/ivacaftor shows lung function boost Vertex's tezacaftor/ivacaftor shows lung function boost

    Vertex's tezacaftor/ivacaftor shows lung function boost. The combination therapy is currently under review in Europe and the US. ... US biotech Vertex has revealed positive phase III results of its tezacaftor/ivacaftor treatment for the underlying cause

  • FDA broadens use of cystic fibrosis drug Kalydeco FDA broadens use of cystic fibrosis drug Kalydeco

    Vertex Pharma is celebrating after the FDA once again extended the labelling for its cystic fibrosis therapy Kalydeco so that more patients with the genetic disease are eligible to use it. ... Vertex says the new labelling - which was initially turned

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Reckitt Benckiser(RB) is spinning out its pharma business unit, under the name Indivior. ... On a mission. Continuing its trend of helping companies monetise their future income streams, Royalty Pharma is buying royalties in Vertex Pharmaceutical's

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics